We provide evidence that the Unc-51-like kinase 1 (ULK1) is activated during engagement of the type I interferon (IFN) receptor (IFNR). Our studies demonstrate that the function of ULK1 is required for gene transcription mediated via IFN-stimulated response elements (ISRE) and IFNg activation site (GAS) elements and controls expression of key IFN-stimulated genes (ISGs). We identify ULK1 as an upstream regulator of p38a mitogen-activated protein kinase (MAPK) and establish that the regulatory effects of ULK1 on ISG expression are mediated possibly by engagement of the p38 MAPK pathway. Importantly, we demonstrate that ULK1 is essential for antiproliferative responses and type I IFN-induced antineoplastic effects against malignant erythroid precursors from patients with myeloproliferative neoplasms. Together, these data reveal a role for ULK1 as a key mediator of type I IFNR-generated signals that control gene transcription and induction of antineoplastic responses.
. These cytokines have clinical activity against viral infections and several human malignancies (Hervas-Stubbs et al., 2011; Bekisz et al., 2013; Kotredes and Gamero, 2013; Platanias, 2013; Stein and Tiu, 2013) . Despite continuing efforts to define the precise mechanisms by which IFNs generate antineoplastic responses, the sequence of events and the specific coordination of different IFN-activated signaling cascades required for such responses remain incompletely defined (Platanias, 2013) .
All type I IFNs bind to type I IFN receptor (IFNR), the engagement of which activates JAK-STAT (Janus-activated kinasesignal transducer and activator of transcription) signaling pathways (Platanias, 2005; Stark and Darnell, 2012; Ivashkiv and Donlin, 2014) . Beyond these pathways, activation of several other IFN-signaling cascades occurs during engagement of IFN receptors, including the p38 mitogen-activated protein kinase (MAPK) pathway (Uddin et al., 1999; Li et al., 2004) , the phosphatidylinositol 3-kinase (PI3K)-AKT pathway (Kaur et al., 2008a (Kaur et al., , 2008b , and the mammalian target of rapamycin complex 1 (mTORC1) and mTORC2 signaling cascades (Kaur et al., 2007 (Kaur et al., , 2012 . The functions of these pathways are essential for optimal transcription and/or mRNA translation of various interferon-stimulated genes (ISGs) that are needed for the induction of IFN-responses (Kaur et al., 2007 (Kaur et al., , 2008b .
Although the relevance and functional importance of mTORC1 signals in promoting functional IFN responses is well established (Kaur et al., 2007) , the precise mechanisms and distinct roles of downstream mTORC1 effectors in the process remain to be defined. Previous work has demonstrated that activated mTORC1 prevents autophagy by phosphorylation of serine 757 (Ser757) of Unc-51-like kinase 1 (ULK1) and by disrupting the interaction between ULK1 and AMP-activated protein kinase (AMPK) (Kim et al., 2011) . ULK1 and ULK2 are the closely related mammalian homologs of the serine/threonine autophagy-related (ATG) protein kinase ATG1, the first identified ATG product in yeast, and both are involved in the regulation of autophagy (Alers et al., 2012) . In the present study, we examined whether ULK1 is engaged in IFN signaling and what role it plays in the induction of type I IFN-mediated responses. Our studies provide evidence implicating ULK1 in type I IFN signaling and transcriptional activation of ISGs and define a mechanism by which such ULK1-mediated activity occurs in the IFN system, possibly involving regulation/activation of p38 MAPK.
RESULTS

Type I IFN-Induced Phosphorylation of ULK1 on Serine 757 Is AKT Dependent
In initial studies, we examined whether type I IFN treatment induces phosphorylation of ULK1 in IFN-sensitive cells. Treatment of different IFN-sensitive malignant hematopoietic cell lines (U937, KT-1, and U266) with human IFNb induced phosphorylation of ULK1 at the mTORC1 phosphorylation site (Kim et al., 2011) , Ser757 ( Figures 1A-1C ). In contrast, there was no IFNb-dependent induction of phosphorylation of ULK1 at Ser555 ( Figures 1A-1C ), the amino acid residue phosphorylated by AMPK (Bach et al., 2011) . Previous studies have established that the serine/threonine protein kinase AKT is activated downstream of PI3K (Kaur et al., 2008a) and mTORC2 (Kaur et al., 2012) during engagement of the type I IFNR and regulates downstream engagement of mTORC1 (Kaur et al., 2008b) . We examined whether engagement of ULK1 in IFN-signaling requires upstream AKT activity. For this, we determined the effects of IFNb treatment on the phosphorylation of ULK1 using Akt1/2 double-knockout (Akt1/2 À/À ) mouse embryonic fibroblasts (MEFs) (Peng et al., 2003) . Treatment of Akt1/2 +/+ MEFs with mouse IFNb resulted in phosphorylation of ULK1 on Ser757 ( Figure 1D ). However, IFNb-induced phosphorylation of ULK1 on Ser757 was defective in Akt1/2 À/À MEFs ( Figure 1D ).
In contrast, there was no IFNb-dependent induction of phosphorylation of ULK1 at Ser555 in both Akt1/2 +/+ and Akt1/2 À/À MEFs ( Figure 1D ). Together, these data suggest that upstream AKT activity is essential for regulation of type I IFN-induced phosphorylation of ULK1 on Ser757.
Requirement of ULK1/2 Activity for Transcriptional Activation of Type I IFN-Stimulated Genes Our data establish that ULK1 is activated via the type I IFNR.
As the generation of IFN responses depends on expression of ISGs and their protein products (Darnell et al., 1994; Stark and Darnell, 2012; Cheon et al., 2014) , we initiated studies to determine whether ULK1 controls type I IFN-dependent gene transcription. Initially, we determined whether ULK1/2 activity is required for transcriptional activation via IFN-stimulated response elements (ISRE) or IFNg activation site (GAS) elements in luciferase reporter assays, using MEFs with targeted disruption of both the Ulk1 and Ulk2 genes. For these studies, we used Ulk1/2 +/+ and Ulk1/2 À/À MEFs (Cheong et al., 2011) , as ULK1 and ULK2 kinases were previously shown to have at least partially redundant functions in fibroblasts (Kundu et al., 2008; Lee and Tournier, 2011 Figure 2C ), whereas only 264 genes were inducible in Ulk1/2 À/À MEFs ( Figure 2D ). Notably, although 225 genes were induced in both Ulk1/2 +/+ and Ulk1/2 À/À MEFs ( Figures 2E   and 2F ), the expression of 84 of these genes was significantly higher in the Ulk1/2 +/+ MEFs compared to the Ulk1/2 À/À MEFs ( Figure 2F and Table S1 , genes highlighted in red). 131 genes were found to be induced only in the Ulk1/2 +/+ MEFs (Figures  2E and 2G; Table S2 ), whereas 39 unique genes were induced in the Ulk1/2 À/À MEFs (Figures 2E and 2H; Table S3 ). The differentially expressed genes between Ulk1/2 +/+ and Ulk1/2 À/À MEFs were classified among biochemical pathways using the KEGG database (Tables S4, S5 , and S6). Most of the genes whose transcriptional induction by IFNb treatment was defective or decreased in Ulk1/2 À/À MEFs could be classified among biochemical pathways that regulate adaptive and innate immunity, as well as antiviral, antiproliferative, and pro-apoptotic responses (Table S4 , genes highlighted in red and green; Table S5 ). In contrast, genes induced by IFNb only in Ulk1/2 À/À MEFs could be classified among biochemical pathways that are involved in cell adhesion and DNA transcription (Table S6) . A functional gene network, generated using IPA 2014 software, is shown in Figure S1B and demonstrates relationships among the 215 genes whose expression is defective or decreased in the absence of Ulk1/2. In further studies, we confirmed the requirement for ULK1/2 activity in the expression of several key ISGs using qRT-PCR ( Figures 3A-3I ). Among the genes whose expression was found defective in the absence of Ulk1/2 were Cxcl10 (Zhang et al., 2005) and Eif2ak2 (García et al., 2006; McAllister and Samuel, 2009) , both of which are involved in the induction of antiviral effects and control of apoptosis. The induction of several other genes whose function was necessary for generation for IFN biological responses was also defective in Ulk1/2 À/À cells, including
Irgm2 (Hunn et al., 2008) , Gch1 (Rani et al., 2007; Alp and Channon, 2004) , Ifit3 (Schmeisser et al., 2010; Liu et al., 2011) ; Oasl2 (Zhu et al., 2014) , Irf7 (Sharma et al., 2003; Honda et al., 2005; Colina et al., 2008) , Irf9 (Darnell et al., 1994; van Boxel-Dezaire et al., 2006) , and Isg54/Ifit2 (Yang et al., 2012) (Figures 3A-3I ).
To determine whether ULK1 expression is required for transcriptional activation of IFN-induced genes in other cell types, studies were performed with human U937 cells in which ULK1 was knocked down using specific small interfering RNAs (siRNAs) ( Figure 3J ). We found decreased IFN-inducible mRNA expression of ISG15 and ISG54 (Figures 3K and 3L) , genes with crucial roles in the induction of IFN responses (Lenschow et al., 2007; Yang et al., 2012) , further establishing a key role for ULK1 in type I IFN signaling. It has been extensively established that ULK1 regulates the induction of autophagy (Kim et al., 2011; Russell et al., 2013) . In addition, there is also evidence for IFN-dependent induction of autophagy (Ambjørn et al., 2013; Schmeisser et al., 2014) . We determined whether inhibition of autophagy modulates IFN-dependent transcriptional activation. The effects of siRNAmediated knockdown of ATG5, a protein required in the early stages of autophagosome formation (Mizushima et al., 2001) , were initially determined. No significant differences in IFNdependent Isg15, Isg54, and Irf9 mRNA expression were observed between control cells and cells in which ATG5 was knocked down (Figures 4A-4D ). Consistent with this, treatment of cells with the autophagy inhibitors chloroquine or bafilomycin A1 (Klionsky et al., 2008) did not significantly affect ISG mRNA expression ( Figures 4E-4G ), further establishing that ULK1 promotes type I IFN-dependent transcriptional activation of key target genes in an autophagy-independent manner.
ULK1 Mediates Type I IFN-Dependent Activation of p38 MAPK
To define the mechanisms by which ULK1 activity may regulate type I IFN-dependent transcriptional activation, we examined whether it is required for activation of pathways that control type I IFN-dependent transcriptional activation of sensitive genes. As activation of Stat1 is essential for transcriptional induction of genes that contain ISRE or GAS elements in their promoters (Stark and Darnell, 2012) , we first determined if phosphorylation/activation of Stat1 is Ulk1/2 dependent in MEFs. IFNb-dependent phosphorylation of Stat1 on serine 727 and tyrosine 701 was inducible in both Ulk1/2 +/+ and Ulk1/2 À/À MEFs ( Figure 5A ), indicating that the functions of ULK1/2 are not required for type I IFN-induced activation of Stat1. As Stat1 is a key type I IFN-regulated protein involved in complexes that control both ISRE-and GAS-dependent transcription, these studies suggested that the effects of ULK1/2 on type I IFN-inducible transcriptional activation are independent of modulation of the classical STAT pathways. Previous studies have demonstrated that the p38 MAPK pathway complements the function of STAT pathways and plays a critical role in type I IFN-induced transcriptional activation via both ISRE and GAS elements (Uddin et al., 1999 (Uddin et al., , 2000 Li et al., 2004) . We examined the possibility that the effects of ULK1/2 on ISG transcription are mediated by effects on p38 MAPK activity. We found that IFNb-induced phosphorylation of p38 MAPK was substantially decreased in Ulk1/2 À/À MEFs as compared to Ulk1/2 +/+ MEFs ( Figure 5B ). Additionally, this defective p38 MAPK phosphorylation could be rescued by ectopic re-expression of wild-type ULK1 (ULK1 WT), but not a kinase-inactive ULK1 mutant (ULK1 K46I) (Egan et al., 2011) ( Figure 5C ). Complementation of Ulk1/2 À/À MEFs with ULK1
WT also restored IFN-induced transcriptional activation via GAS elements ( Figure 5D ). Moreover, we found that p38a MAPK is phosphorylated by ULK1 kinase in in vitro assays (Figures 5E and S2) Figure S3 ). Specifically, at least a 50-fold reduction in infective dose was required to induce comparable EMCV-induced cytopathic effects (CPE) in the Ulk1/2 À/À MEFs compared with the Ulk1/2 +/+ MEFs ( Figure S3 ). Moreover, IFNa-induced antiviral dose-response data indicated that Ulk1/2 À/À cells are also less responsive to mouse IFNa treatment compared with Ulk1/2 +/+ cells ( Figure 6A ). Together, these data show that Ulk1/2 À/À MEFs are more sensitive to viral infection and less sensitive to the antiviral effects of IFNa compared with Ulk1/2 +/+ MEFs, establishing that engagement of Ulk1/2 is required for the control of type I IFN-generated antiviral responses in MEFs. We also determined whether ULK1 is required for the generation of type I IFN-antiproliferative responses. For this purpose, we performed studies involving siRNA-mediated knockdown of ULK1 in U937 cells, followed by assessment of IFNb-inhibitory responses on leukemic blast colony-forming unit (CFU-L) colony growth. As shown in Figure 6B , inhibition of expression of ULK1 partially reversed suppression of CFU-L colony formation by IFNb treatment, implicating ULK1 as a signaling element required for the generation of type I IFN-antiproliferative effects. and three independent experiments for (B), using technical triplicates in each experiment. Statistical analyses were performed using Student's t test (*p < 0.05; **p < 0.01). Table S1 ).
(G) Hierarchical clustering of differentially expressed genes only in Ulk1/2 +/+ MEFs (see list of genes in Table S2 ).
(H) Hierarchical clustering of differentially expressed genes only in Ulk1/2 À/À MEFs (see list of genes in Table S3 ).
All annotations presented here are based on statistical analyses and are presented with p values after false discovery rate correction. Only annotations with p values < 0.05 are shown. See also Tables S4, S5 , and S6 and Figure S1 . U937 cells after siRNA transfection are shown. Expression levels of the indicated genes were determined using GAPDH for normalization. Data are expressed as fold change over untreated samples (A-I) or control siRNA untreated samples (K and L) and bar graphs represent means ± SE of three independent experiments for (A)-(F) and (L) and four independent experiments for (G)-(I) and (K). Statistical analyses were performed using Student's t test between treated groups (*p < 0.05; **p < 0.01; ***p < 0.001).
ULK1 Is Critical for IFN Regulation of Normal Hematopoiesis and the Generation of IFN Responses in Myeloproliferative Neoplasms
As type I IFNs are potent regulators of normal hematopoiesis (Platanias, 2005) , in subsequent studies, we determined if engagement of ULK1 activity is necessary for the generation of growth-inhibitory responses on normal CD34 + -derived hematopoietic precursors. For this purpose, we used specific siRNAs to knock down ULK1 expression in primary normal human bone marrow progenitors and examined the effects of this knockdown on the inhibitory effects of IFNa on CD34 + -derived erythroid and myeloid precursors. As expected, treatment with human IFNa suppressed the growth of normal myeloid (granulocyte-macrophage colony-forming unit [CFU-GM]) and early erythroid (erythroid burst-forming unit [BFU-E]) progenitors in clonogenic assays in methylcellulose ( Figure 7A ). However, these suppressive effects were reversed by ULK1 knockdown (Figure 7A (B-D) MEFs transfected with control siRNA or ATG5-specific siRNA were treated with mouse IFNb for 6 hr, and mRNA expression for the indicated genes was assessed by qRT-PCR, using GAPDH for normalization. Data are expressed as fold change over control siRNA untreated (UT) samples, and bar graphs represent means ± SE of three independent experiments. (E-G) MEFs were treated with chloroquine (CQ), bafilomycin A1 (BFA), and/or mouse IFNb. mRNA expression for the indicated genes was assessed by qRT-PCR, using GAPDH for normalization. Data are expressed as fold change over control untreated (UT) cells, and bar graphs represent means ± SE of five independent experiments for (E) and (G) and three independent experiments for (F).
cating key and essential roles for ULK1 in the control of normal hematopoiesis by type I IFNs.
In further studies, we examined whether the engagement of ULK1 by the type I IFNR is essential for generation of antineoplastic responses. It is well established that polycythemia vera (PV) and other Philadelphia-chromosomenegative myeloproliferative neoplasms (MPNs) are sensitive to type I IFN therapy, and type I IFN treatment is currently used for the treatment of such neoplasms (Tefferi and Vainchenker, 2011; Kiladjian et al., 2011; Cassinat et al., 2014) . We determined whether ULK1 is required for generation of type I IFN-dependent growth-inhibitory effects on malignant erythroid progenitors from patients with PV. When primary peripheral blood mononuclear PV cells were treated with IFNb, we observed induction of ULK1 phosphorylation on serine 757 ( Figure 7B ). Importantly, when the effects of type I IFN treatment on malignant erythroid progenitors from five different MPN patients were assessed, we found that siRNA-mediated targeted inhibition of ULK1 expression reversed the suppressive effects of IFNb on primitive malignant erythroid precursors in vitro ( Figure 7C ). Thus, ULK1 engagement via the type I IFNR appears to be essential for generation of antineoplastic effects in MPNs.
Next, we determined whether ULK1 expression is upregulated in the peripheral blood of MPN patients. Specific analysis for ULK1 gene expression from a previously reported microarray profiling study in neutrophils from a cohort of patients with chronic MPNs (Rampal et al., 2014) showed that ULK1 expression is increased in different groups of MPN patients, including patients with PV, essential thrombocythemia (ET), and myelofibrosis (MF) ( Figure 7D ). The upregulation of expression of ULK1 was also seen in another independent group of MPN patients ( Figure 7E ) using RT-PCR analysis for ULK1 mRNA expression, establishing upregulation of ULK1 expression in MPNs and suggesting a mechanism to explain the unique sensitivity of these neoplasms to the effects of type I IFNs.
DISCUSSION
Type I IFNs are cytokines with important biological effects in vitro and in vivo and have been used extensively in the treatment of various malignancies, viral syndromes, and autoimmune disease in humans (Borden et al., 2007; Cheon et al., 2014; Platanias, 2013) . The important biological and therapeutic properties of type I IFNs reflect the induction of expression of key genes via the type I IFNR that mediate diverse biological responses, including antineoplastic, immune modulatory, and antiviral effects (Cheon et al., 2014; Kroczynska et al., 2014 ). The precise mechanisms accounting for the transcriptional activation and mRNA translation of such ISGs have been the focus of extensive work that led to the original discovery of JAK-STAT pathways (Darnell et al., 1994; Platanias, 2005; Stark and Darnell, 2012) . Besides the classical JAK-STAT signaling cascades, the type I IFNR engages several other cellular pathways in normal and Bar graphs show means ± SE of three independent experiments using technical triplicates in each experiment. Statistical analyses were performed using Student's t test (*p < 0.05).
(E) U937 cells were starved overnight prior to IFNb treatment and then treated with human IFNb for 5, 10, and 30 min, as indicated. After cell lysis, equal amounts of protein were immunoprecipitated with either ULK1-specific antibody or control non-immune rabbit IgG (RIgG). In vitro kinase assays to detect ULK1 activity were subsequently performed on the immunoprecipitates, using p38a MAPK recombinant inactive protein as an exogenous substrate. (Left and top) Immunoblot demonstrating total immunoprecipitated ULK1 expression used in each condition for the in vitro kinase assay. (Left and bottom) Autoradiography film demonstrating ULK1-induced phosphorylation of p38a MAPK after IFNb treatment is shown. Note: a lane between ULK1 and RIgG immunoprecipitates was loaded with 13 loading dye for best separation between the wells. (Right) Bands were quantified by densitometry using ImageJ software, and data are expressed as ratios of 32 P p38a MAPK over total immunoprecipitated ULK1. See also Figure S2 .
malignant cells (Platanias, 2005; van Boxel-Dezaire et al., 2006; Gonzá lez-Navajas et al., 2012) , the functions of which are required for the generation of type I IFN-dependent biological responses (Platanias, 2005) . Among them, the p38 MAPK cascade appears to act as an auxiliary pathway, necessary for optimal transcription of ISGs, without modulating elements of the STAT-pathway (Platanias, 2005) . Despite a better understanding of the mechanisms of type I IFN signaling in the past decades, several questions have remained unanswered, particularly the mechanisms that define signaling specificity. Although, in some cases, selective use of the type I IFNR subunits may account for differential gene expression among distinct type I IFNs (de Weerd et al., 2013), the precise effectors of such specific pathways and the potential interactions with other cytokine receptors remain to be defined (Kaur and Platanias, 2013) . Also, there is a need to identify cellular elements linking pathways that control IFN-dependent gene transcription to the ones that regulate subsequent mRNA translation of ISGs, as this should allow better understanding of the mechanisms that account for specificity of expression of ISG products.
In the present study, we provide evidence that the kinase ULK1 is phosphorylated by engagement of the type I IFNR at serine 757, an mTORC1 phosphorylation site known to inhibit ULK1 in pathways that control the initiation of autophagy (Kim et al., 2011) . Furthermore, our data show that ULK1 is activated after engagement of the type I IFNR and that its activated form can, either directly or through intermediate kinases, phosphorylate the p38 MAPK in immune complex kinase assays in vitro. This suggests that during type I IFN treatment, the pro-autophagic functions of ULK1 are blocked, and instead, ULK1 activity is possibly re-directed toward regulation of the p38 MAPK pathway. Consistent with this, type I IFN-inducible activation of the p38 MAPK pathway is defective in cells with targeted disruption of the Ulk1/2 genes and appears to result in defective downstream ISG transcription. Moreover, type I IFN-induced activation of p38 MAPK and transcriptional activation via GAS elements is restored by ectopic expression of ULK1 WT protein in Ulk1/2 À/À MEFs. Hence, it is possible that for optimal activation of p38 MAPK pathway in the type I IFN system, the activities of both ULK1 and MKK3/6 (Li et al., 2005) are required. Notably, the effects of ULK1 on ISG expression appear to reflect selective regulation of the p38 MAPK pathway, as functional engagement of STAT1 is intact in Ulk1/2 À/À cells.
In previous studies, we had demonstrated that AKT is required for mRNA translation of ISGs, but not ISG transcription (Kaur et al., 2008b) . In the present study, we provide evidence that Akt1/2 activity is required for type I IFN-induced ULK1 phosphorylation at serine 757. Furthermore, given that transcription of ISGs is defective in Ulk1/2 À/À MEFs and in U937 cells in which ULK1 has been knocked down, it is possible that another type I IFN-activated kinase(s) act(s) upstream of ULK1 during engagement of the type I IFNR, and concomitant regulation of ULK1 by such kinase may be necessary for the transcriptional activity of ULK1. Some examples of possible kinases are PKC-d and ERK1 kinases, which have been identified as potential kinases of ULK1 (Mack et al., 2012) and are activated downstream of type I IFNR (Platanias, 2005) , but this remains to be determined in future studies. The potential engagement of ULK1 in type I IFN signaling has important functional implications for the generation of the effects of type I IFNs. Our studies provide evidence for an involvement of ULK1 in the induction of both type I IFN-antiviral responses and growth-inhibitory activities. They also suggest key and essential roles for ULK1 in the generation of the suppressive regulatory effects of type I IFNs on normal hematopoiesis, by demonstrating that ULK1 knockdown reverses suppression of myeloid (CFU-GM) and early erythroid (BFU-E) hematopoietic progenitors. Most importantly, our data identify ULK1 as an essential element for the generation of the antineoplastic effects of type I IFNs on primitive malignant hematopoietic precursors from patients with PV, an MPN where IFN treatment has major clinical activity (Tefferi and Vainchenker, 2011) . Remarkably, when expression of ULK1 mRNA was specifically analyzed in a large cohort of patients with different MPNs, we found significant increases in ULK1 expression in different subtypes of MPNs, including PV, essential thrombocytosis, and myelofibrosis. There is prior evidence that the p38 MAPK pathway is involved in the generation of type I IFN-antileukemic effects (Mayer et al., 2001) , while other studies have shown that p38 MAPK activation is essential for the generation of the inhibitory effects of type I IFNs on JAK2V617F-positive hematopoietic progenitor cells from MPN patients (Lu et al., 2010) . Our findings suggest a mechanism by which ULK1 and p38 MAPK are engaged in type I IFN-signaling in MPNs and, most importantly, provide an explanation for the unique sensitivity of these malignancies to the effects of type I IFNs, due to overexpression of ULK1. It should be noted that in a recent study, ULK1 was shown to inhibit STING activity, leading to inhibition of IRF3, and consequent suppression of type I IFN production (Konno et al., 2013) .
These events appear to function as a negative-feedback control mechanism to prevent sustained transcription of ISGs (Konno et al., 2013) and limit development of IFN-dependent autoimmune inflammatory disorders (Gall et al., 2012) . The results of our studies, taken in context with the report of Konno et al. (2013) , suggest a dual regulatory role for ULK1 in the control of type I IFN responses, acting as a ''molecular switch'' in the IFN system that regulates the balance and duration of IFN biological responses. In this model, ULK1 appears to regulate directly early signals that control ISG expression and induction of type I IFN responses. At the same time, a more delayed ULK1-mediated effect appears to be the suppression of type I IFN production by suppressing STING activity, thus limiting/optimizing the response. The recognition of this unique role for ULK1 should have important clinical-translational implications, as modulation of ULK1 activity may be used as an approach to selectively enhance the activity of type I IFNs on MPN cells. (D) Boxplot shows gene expression of ULK1 in neutrophils in a large independent cohort of normal individuals (normal, n = 11) and patients with PV (n = 13), ET (n = 24), and MF (n = 18). Statistical analyses were performed using Student's t test comparing expression in each MPN group to the normal group (**p < 0.01; ***p < 0.001). (E) qRT-PCR analysis for ULK1 mRNA expression in neutrophils isolated from different patients with MPNs (MPN1-8) and age-matched controls (CTRL1-4). Expression levels of the ULK1 gene were determined using GAPDH for normalization. Data are expressed as fold change over CTRL4, and bar graphs represent means ± SD for two independent assays.
EXPERIMENTAL PROCEDURES
Materials and some of the methods can be found in the Supplemental Experimental Procedures.
Cells and Cell Culture U937, U266, and KT-1 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. The immortalized Akt1/2 +/+ and Akt1/2 À/À MEFs were kindly provided by Dr. Nissim Hay (University of Illinois at Chicago) (Peng et al., 2003) . The immortalized Ulk1/2 +/+ and Ulk1/ 2 À/À MEFs have been described previously (Cheong et al., 2011) . MEFs were cultured in DMEM medium supplemented with 10% FBS and antibiotics. Peripheral blood from patients with PV was collected after obtaining consent approved by the institutional review board of Northwestern University. Additionally, blood samples were collected from patients with MPNs and controls at Albert Einstein School of Medicine, under an institutional review board-approved study.
Immunoblotting Cells were treated, transfected, and lysed as described in Supplemental Experimental Procedures. Equal amounts of total cell lysates were resolved by SDS-PAGE and processed for immunoblotting essentially as in our previous studies (Uddin et al., 1999; Kaur et al., 2007; Kroczynska et al., 2009 ).
Luciferase Reporter Assays
Ulk1/2 +/+ and Ulk1/2 À/À MEFs were co-transfected with a b-galactosidase expression vector and either an ISRE-luciferase or 8X GAS-luciferase construct. Luciferase activities were measured and normalized to b-galactosidase activity as in previous studies (Uddin et al., 1999) . See Supplemental Experimental Procedures for a detailed description.
Microarray Analysis
Total RNA was isolated from Ulk1/2 +/+ and Ulk1/2 À/À MEFs untreated or treated with IFNb (n = 3), and labeled cRNA was hybridized to MouseWG-6 v2.0 Expression BeadChips. See Supplemental Experimental Procedures for a detailed description.
qRT-PCR qRT-PCR was carried out using commercially available 6-carboxyfluoresceinlabeled probes and primers (Applied Biosystems). The mRNA amplification was calculated as described previously (Kaur et al., 2007) , and the data were plotted as the increase of fold change as compared with control samples. See the Supplemental Experimental Procedures for a detailed description.
Immunoprecipitations and In Vitro Kinase Assays
In vitro kinase assays to detect ULK1 kinase activity in cells treated with IFNb were performed essentially as in previous studies (Kroczynska et al., 2009 ). MAPK14 (p38a MAPK) recombinant human inactive protein was used as an exogenous substrate. See the Supplemental Experimental Procedures for a detailed description.
Antiviral Assays
The antiviral effects of mouse IFNa on Ulk1/2 +/+ and Ulk1/2 À/À MEFs were determined in assays using ECMV as the challenge virus, as in previous studies (Kaur et al., 2012) .
Hematopoietic Cell Progenitor Assays
The effects of ULK1 knockdown were assessed in leukemic (CFU-L), erythroid (BFU-E), or myeloid (CFU-GM) colony formation using clonogenic assays in methylcellulose (STEMCELL Technologies) in the absence or presence of type I IFNs, as in previous studies (Mayer et al., 2001; Joshi et al., 2009; Kroczynska et al., 2012; Mehrotra et al., 2013; Kaur et al., 2014) . See the Supplemental Experimental Procedures for a detailed description.
Statistical Analyses
Student's t test was used for comparison of one observation between two groups. One-way ANOVA was used to compare more than two groups followed by Tukey's test. Differences were considered statistically significant when p values were less than 0.05.
ACCESSION NUMBERS
The NCBI GEO accession number for the microarray data reported in this paper is GSE60778. 
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